The scrutiny centers on the company’s April 29, 2026, financial disclosure, where management revealed adjusted earnings per share of $0.99. During the same call, leadership lowered its full-year EPS guidance from a previous range of $4.95–$5.15 down to $4.80–$5.00. Executives attributed these financial headwinds to margin pressures in the Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS) segments, specifically citing a product recall involving a PDx supplier.

Following the announcement, GE HealthCare shares fell $9.01, closing at $59.49. The situation intensified on July 23, 2026, when the company confirmed the departure of Chief Financial Officer Jay Saccaro. Law firm Glancy Prongay Wolke & Rotter LLP has invited investors who sustained losses to contact their Los Angeles office to discuss potential claims or whistleblower opportunities related to the SEC program.